Cancer vaccines may be available before 2030. What do you know about mRNA vaccines?

The mRNA vaccine is a recombinant vaccine of non-coding DNA sequences. It can induce the body to produce an immune response against a specific virus strain under antigen stimulation, and at the same time obtain appropriate expression through its specific antigen.

Adjust the mRNA sequence to generate an antigen-specific immune response.

The cost of mRNA technology is lower.

mRNA technology has the characteristics of low manufacturing cost, high production efficiency and short preparation time. A series of technologies such as vaccine technology and stem cell technology that have emerged in recent years have also greatly promoted the development of mRNA vaccines.

The application of mRNA technology will play a major role in improving human health, promoting medical development, and promoting biotechnology progress.

The production of mRNA is easy, fast and safe.

?mRNA vaccines do not rely on cell culture technology. Existing in vitro transcription technology can produce large-scale RNA vaccines very quickly and cheaply; compared with the traditional 5-6 month vaccine production cycle, as long as the virus gene sequence is mastered,

It can produce mRNA vaccines, and the production and preparation of vaccine samples can be completed within 40 days. The entire production process only involves biochemical synthesis, so there is no risk of viral infection, which is easier and safer.

In addition, as a vaccine, mRNA can activate humoral immunity and cellular immunity at the same time, with remarkable effects.

What are the advantages and disadvantages of mRNA vaccines?

The mRNA vaccine injects the virus directly into the human body.

Viruses have codes for antigenic proteins called RNA.

After the human body is injected with a vaccine, it will use its own cells and viral antigen proteins to generate innate immunity.

Today, this technology has completely changed the traditional way of vaccine production and is also the most advanced technology in vaccines.

In addition, there is no need for multiple vaccinations after vaccination, which can save a lot of vaccination time and cost.

The disadvantage is that mRNA is currently a new and immature technology, so there are unpredictable risks.

And vaccine transportation requirements are very demanding.